What happened with BNGO today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Bionano Genomics helps research and clinical laboratories identify structural changes in DNA. Its Saphyr and Stratys systems image long DNA molecules and build physical genome maps, a process called optical genome mapping (OGM). Customers buy instruments and then purchase chips and reagents as they process samples. Some receive instruments without an upfront charge in exchange for minimum consumable-purchase commitments. Product sales account for most revenue, with consumables the largest revenue line.
The company also sells Ionic Purification systems for preparing DNA and VIA software for interpreting genome data from OGM, sequencing and microarrays. VIA earns subscription revenue and offers pay-per-sample pricing in sequencing and microarray applications. A smaller laboratory-services business processes samples for customers without their own systems and offers a diagnostic test for suspected facioscapulohumeral muscular dystrophy type 1 through Bionano Laboratories; several former diagnostic services have been discontinued.
Bionano now emphasizes increasing use of systems already installed rather than placing new instruments. Revenue therefore depends heavily on how many samples customers process and on their research budgets. It also relies on a single contract manufacturer for instruments and limited suppliers for certain reagents.
Its systems are sold for research use only, not diagnosis; marketing them for diagnostic use requires applicable regulatory authorization. Bionano Laboratories provides its diagnostic service separately as a laboratory-developed test. Bionano also needs additional financing to continue operating, and its ability to secure that funding remains uncertain.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Bionano Genomics’ results hinge on financing and greater use of its installed mapping systems, while Oxford Nanopore Technologies and privately held Nabsys are important competitors missing from this list.
PacBio competes with Bionano for spending by researchers and clinical laboratories studying large changes in DNA structure: PacBio reads long stretches of DNA, while Bionano builds physical genome maps. Watch demand for PacBio’s HiFi sequencing instruments and consumables as an indication of where those laboratories put their workflow budgets.
QIAGEN competes with Bionano in laboratory genome-analysis workflows, selling products that prepare biological samples, test their molecular contents and interpret the results; Bionano sells DNA extraction, mapping and interpretation tools. QIAGEN’s consumables and related revenue is the line to watch for spending on its integrated laboratory workflows.
Illumina offers both alternatives and complements to Bionano’s genome mapping, selling DNA sequencing and microarray tools to the same kinds of genomic laboratories. Those laboratories’ use of sequencing and arrays also matters to Bionano’s VIA software, which charges per sample to interpret genetic-disease and cancer data independently of its mapping systems.
10x Genomics and Bionano both depend on laboratories funding advanced genomic experiments: 10x sells tools to study individual cells and their locations in tissue, while Bionano sells genome-mapping systems. Demand for 10x’s research consumables among academic, government and biopharmaceutical customers is a useful signal of experimental spending in their shared customer groups.
Illumina Inc earningsILMN
Illumina’s report will show how genomic labs are using sequencing and microarrays, workflows that can also generate per-sample demand for Bionano Genomics’ VIA software.
Look at Illumina’s consumables-related revenue as a signal of use, alongside its comments on sequencing and microarray demand. Stronger use would suggest more activity in workflows that could bring Bionano Genomics VIA sample revenue without requiring a Bionano system placement; weaker use would point to pressure on that software-demand channel, though Illumina’s results alone cannot establish Bionano’s revenue.
Pacific Biosciences of California, Inc. earningsPACB
PacBio’s report will show whether researchers and clinical labs are still spending on long-read sequencing tools and consumables, from the same genomic research budgets Bionano Genomics seeks.
See whether demand for HiFi instruments and consumables strengthens together. Strength in both would show labs are still funding advanced genomic research, while Bionano Genomics must still compete for those budgets. Weakness in both would point to tighter workflow budgets among shared customer groups and potentially more pressure on Bionano system and consumables sales. PacBio sequences long DNA reads; Bionano builds physical genome maps, so they are not the same product.
Bionano Genomics, Inc. earningsThis company
Bionano Genomics’ report will show whether consumables and VIA software use by existing customers can grow revenue while the business uses less cash.
Read consumables and software revenue alongside instrument revenue and cash used in operating activities. Growth in consumables and software with lower cash use would show that revenue from existing customer use is strengthening and reliance on new system placements may be easing. Weakness in those revenue streams or continued heavy cash use would show that the shift has not resolved the funding pressure and the company still needs outside financing.
